Your browser doesn't support javascript.
loading
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Arcaini, Luca; Lamy, Thierry; Walewski, Jan; Belada, David; Mayer, Jiri; Radford, John; Jurczak, Wojciech; Morschhauser, Franck; Alexeeva, Julia; Rule, Simon; Cabeçadas, José; Campo, Elias; Pileri, Stefano A; Biyukov, Tsvetan; Patturajan, Meera; Casadebaig Bravo, Marie-Laure; Trnený, Marek.
Afiliação
  • Arcaini L; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Lamy T; Department of Haematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Walewski J; Department of Haematology, Hôpital Pontchaillou, Rennes, France.
  • Belada D; Department of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland.
  • Mayer J; Fourth Department of Internal Medicine, Haematology, Charles University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.
  • Radford J; Department of Internal Medicine, Haematology and Oncology, University Hospital Brno, Brno, Czech Republic.
  • Jurczak W; The University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
  • Morschhauser F; Department of Haematology, Jagiellonian University Medical College, Kraków, Poland.
  • Alexeeva J; Department of Haematology, Hôpital Claude Huriez, EA 7365 GRITA, Lille, France.
  • Rule S; Department of Haematology Research, Federal Medical Research Centre, Saint Petersburg, Russia.
  • Cabeçadas J; Department of Haematology, Derriford Hospital, Plymouth, United Kingdom.
  • Campo E; Serviço de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal.
  • Pileri SA; Haematopathology Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.
  • Biyukov T; Unit of Haematopathology, European Institute of Oncology, Milan, Italy.
  • Patturajan M; Clinical Research and Development, Celgene Sàrl, Boudry, Switzerland.
  • Casadebaig Bravo ML; Clinical Research and Development, Celgene Corporation, Summit, NJ, USA.
  • Trnený M; Clinical Research and Development, Celgene Sàrl, Boudry, Switzerland.
Br J Haematol ; 180(2): 224-235, 2018 01.
Article em En | MEDLINE | ID: mdl-29193019
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Talidomida / Linfoma de Célula do Manto / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Talidomida / Linfoma de Célula do Manto / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Itália